Displaying 16 - 20 of 50
Mon 09 May 2016
Anna Jewell, Pancreatic Cancer UK’s Director of Operations, has been accepted as a lay member of the NICE guidelines committeeRead More about 'Anna Jewell joins NICE guidelines committee'
Wed 30 March 2016
We are extremely encouraged by today’s announcement by NICE. We want to see a new appraisal of Abraxane carried out as soon as possible.Read More about 'NICE to consider bringing forward Abraxane reappraisal'
Fri 18 March 2016
Alex Ford, Chief Executive of Pancreatic Cancer UK comments on the decision to retain routine NHS access to Abraxane for eligible patients in Wales.Read More about 'Abraxane retained for use on NHS across Wales'
Fri 29 January 2016
The National Institute of Health and Care Excellence (NICE) has announced it will be assessing a new drug that might offer benefit to some pancreatic cancer patients.Read More about 'NICE to assess potentially new pancreatic cancer drug'
Thu 20 August 2015
The Information Services Division (ISD) Scotland has this week released data showing trends in the likely number of cases of different cancer types over a 25 year period up until 2027. Here's our comment.Read More about 'Scottish incidence predictions for pancreatic cancer'